Six Month Study to Evaluate the Safety and Effectiveness of the Intranasal Lacrimal Neurostimulator
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02526290 |
Recruitment Status :
Completed
First Posted : August 18, 2015
Results First Posted : October 31, 2017
Last Update Posted : October 31, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Dry Eye Syndromes Keratoconjunctivitis Sicca | Device: Intranasal Lacrimal Neurostimulator (Oculeve) | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 97 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Supportive Care |
Official Title: | Single-Arm, Multicenter, Open-Label Study to Evaluate the Safety and Effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator in Participants With Aqueous Tear Deficient Dry Eye |
Actual Study Start Date : | August 31, 2015 |
Actual Primary Completion Date : | April 30, 2016 |
Actual Study Completion Date : | April 30, 2016 |
Arm | Intervention/treatment |
---|---|
Experimental: Active - Device
The Oculeve Intranasal Lacrimal Neurostimulator will be administered two to ten times per day for up to three minutes per administration.
|
Device: Intranasal Lacrimal Neurostimulator (Oculeve)
Neurostimulation device |
- Stimulated Acute Tear Production [ Time Frame: The stimulated and prestimulation (basal) measures were both performed at Day 180. ]Stimulated acute tear production in the study eye at Day 180 as measured by the difference between the Schirmer test score during stimulation and the test score before stimulation (basal). The Schirmer strip is placed just under the eyelid and wicks up the tears. It measures tear production on a linear scale of 0-35 mm.
- Corrected Distance Visual Acuity [ Time Frame: Baseline and 6 months ]Change from baseline (Day 0) in corrected distance visual acuity at Day 180. Corrected visual acuity was obtained using the subject's own glasses (for subjects that wear glasses) and measured in logMAR (log of the Minimum Angle of Resolution) units using an appropriate eye chart. A logMAR score of 0.0 is equivalent to a visual acuity of 20/20 and larger logMAR values indicate a poorer visual acuity (eg. A value of 0.3 corresponds to a visual acuity of 20/40).
- Slit Lamp Biomicroscopy [ Time Frame: 6 months ]Number of subjects with clinically significant (CS) findings noted from the slit lamp biomicroscopy examinations. A slit lamp biomicroscopy examination of the eyelids, cornea, conjunctiva, anterior chamber, and lens was performed at each visit for each eye. The results were graded as normal, abnormal not clinically significant (NCS), or abnormal CS. In addition, the cornea was scored specifically for corneal edema using a 4-point scale (0=None, +1=Mild, +2=Moderate and +3=Severe). An increase in corneal edema grade of two or more was considered clinically significant and evaluated as a potential AE by the investigator.
- Device-related Adverse Events [ Time Frame: 6 months ]Number of subjects who experienced any device-related adverse events.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 22 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subjects with moderate to severe dry eye disease
- Literate, able to speak English or Spanish, and able to complete questionnaires independently
- Willing to sign the informed consent and deemed capable of complying with the requirements of the study protocol
Exclusion Criteria:
- Chronic or recurrent epistaxis, coagulation disorders or other conditions that, in the opinion of the investigator, may lead to clinically significant increased bleeding
- Nasal or sinus surgery (including history of application of nasal cautery) or significant trauma
- Cardiac demand pacemaker, implanted defibrillator or other implanted electronic device
- Diagnosis of epilepsy
- Corneal transplant in either or both eyes
- Participation in any clinical trial with a new active substance or a new device within 30 days of the Screening Visit
- Women who are pregnant, planning a pregnancy, or nursing at the Screening Visit

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02526290
United States, Arizona | |
Cornea & Cataract Consultants of Arizona | |
Phoenix, Arizona, United States, 85032 | |
United States, Massachusetts | |
Andover Eye Associates | |
Andover, Massachusetts, United States, 01810 | |
United States, Tennessee | |
Total Eye Care | |
Memphis, Tennessee, United States, 38119 |
Study Director: | Edward Holland, MD | Cincinnati Eye Institute |
Responsible Party: | Oculeve, Inc. |
ClinicalTrials.gov Identifier: | NCT02526290 |
Other Study ID Numbers: |
OCUN-010 |
First Posted: | August 18, 2015 Key Record Dates |
Results First Posted: | October 31, 2017 |
Last Update Posted: | October 31, 2017 |
Last Verified: | September 2017 |
Dry Eye Syndromes Keratoconjunctivitis Sicca Keratoconjunctivitis Lacrimal Apparatus Diseases Eye Diseases |
Conjunctivitis Conjunctival Diseases Keratitis Corneal Diseases |